1. Scrip
  2. >>Therapy Areas

What The New US Cholesterol Treatment Guidelines Mean For Esperion

 
• By Emily Hayes

Guidelines place high emphasis on low cost, but also outcomes data. Esperion plans to file bempedioc acid next year, but outcomes data won’t be available until 2022.

3d rendering Human Heart

Esperion Therapeutics Inc. foresees a boost for its oral bempedoic acid from the latest round of US cholesterol treatment guidelines, which promote the use of add-on therapies for further LDL-lowering on top of statins and emphasize cost-effectiveness.

Esperion plans to file bempedoic acid, an oral ATP citrate lyase inhibitor, for approval as a monotherapy and in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.